Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paulette A Lyle

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 4, 2003
Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL studyWilliam F Keane, Paulette A Lyle,
Expert Opinion on Pharmacotherapy|October 27, 2004
Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) studyRichard B Devereux, Paulette A Lyle
Cardiology Clinics|August 9, 2005
Kidney disease and cardiovascular disease: implications of dyslipidemiaWilliam F Keane, Paulette A Lyle
Journal of the National Medical Association|December 4, 2003
Hypertension and medical informaticsWilliam McBride, Carlos Ferrario, Paulette A Lyle
Current Cardiology Reports|September 8, 2006
Use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers to prevent atrial fibrillationKristian Wachtell, Richard B Devereux, Paulette A Lyle
Current Hypertension Reports|August 10, 2007
The effect of angiotensin receptor blockers for preventing atrial fibrillationKristian Wachtell, Richard B Devereux, And Paulette A Lyle
Therapeutic Advances in Cardiovascular Disease|January 7, 2009
The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophyKristian Wachtell, Richard B Devereux, Paulette A Lyle, et al.
Expert Opinion on Pharmacotherapy|March 24, 2006
Losartan: lessons learned from the RENAAL studyShahnaz Shahinfar, Paulette A Lyle, Zhongxin Zhang, et al.
Vascular Health and Risk Management|August 21, 2007
Fixed combination of losartan and hydrochlorothiazide and reduction of risk of strokeSverre E Kjeldsen, Paulette A Lyle, Jorge R Kizer, et al.
Kidney International. Supplement|October 16, 2004
Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathyCharles M Alexander, Paulette A Lyle, William F Keane, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 4, 2003
Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL studyWilliam F Keane, Paulette A Lyle,
Expert Opinion on Pharmacotherapy|October 27, 2004
Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) studyRichard B Devereux, Paulette A Lyle
Cardiology Clinics|August 9, 2005
Kidney disease and cardiovascular disease: implications of dyslipidemiaWilliam F Keane, Paulette A Lyle
Journal of the National Medical Association|December 4, 2003
Hypertension and medical informaticsWilliam McBride, Carlos Ferrario, Paulette A Lyle
Current Cardiology Reports|September 8, 2006
Use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers to prevent atrial fibrillationKristian Wachtell, Richard B Devereux, Paulette A Lyle
Current Hypertension Reports|August 10, 2007
The effect of angiotensin receptor blockers for preventing atrial fibrillationKristian Wachtell, Richard B Devereux, And Paulette A Lyle
Therapeutic Advances in Cardiovascular Disease|January 7, 2009
The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophyKristian Wachtell, Richard B Devereux, Paulette A Lyle, et al.
Expert Opinion on Pharmacotherapy|March 24, 2006
Losartan: lessons learned from the RENAAL studyShahnaz Shahinfar, Paulette A Lyle, Zhongxin Zhang, et al.
Vascular Health and Risk Management|August 21, 2007
Fixed combination of losartan and hydrochlorothiazide and reduction of risk of strokeSverre E Kjeldsen, Paulette A Lyle, Jorge R Kizer, et al.
Kidney International. Supplement|October 16, 2004
Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathyCharles M Alexander, Paulette A Lyle, William F Keane, et al.
Pageof 3